

**Comparative Study of Total Dose
Infusion of Iron and Intramuscular Iron
Administration in Treatment of Iron
Deficiency Anemia During Pregnancy**

Thesis

*Submitted for partial fulfillment of the master degree of in
Obstetrics and gynecology*

By:

Samira Ali Mufetah

*M. B. Ch., Al-Tahady University 2006
Resident of Obstetric and Gynecology
In Ibsina Hospital- Sirt - Libya*

Supervised by

Dr. Hazem Fadel El Shahawy

*Professor of Obstetric and Gynecology
Faculty of Medicine - Ain Shams University*

Dr. Nashwa El Said Hassan

*Lecturer in Obstetric and Gynecology
Faculty of Medicine - Ain Shams University*

**Faculty of Medicine
Ain Shams University**

2012



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا إِنَّكَ
أَنْتَ الْعَلِيمُ الْحَكِيمُ

()



*First and foremost, thanks to **Allah** for giving me the will and the patience to finish this work.*

*In a few grateful words, I would like to express my deepest gratitude and appreciation to **Dr. Hazem Fadel El Shahawy** Professor of Obstetric and Gynecology, Faculty of Medicine-Ain Shams University, for his great concern and generous help. Without his generous help, this work would not have been accomplished in its present picture.*

*I am sincerely grateful to **Dr. Nashwa El Said Hassan**, Lecturer in Obstetric and Gynecology, Faculty of Medicine, Ain Shams University, for her kind help and constructive suggestions to achieve this work.*

Lastly, there are no words to express my gratitude to my family who charged me with love and encouragement and to all patients and their families for their participation in this study.



Samira Ali Mufetah

Contents

List of Abbreviations	i
List of Tables	ii
List of Figures	iv
Introduction and Aim of the Work	1
Review of literature	5
* Hematological Changes with pregnancy	5
* Anaemia with Pregnancy	17
* Risk Factor of Anaemia with Pregnancy	19
* Iron Deficiency Anemia during Pregnancy	25
* Management of Iron deficiency Anemia During Pregnancy	52
Patients and Methods	81
Results	87
Discussion	100
Summary	111
Conclusion	113
Recommendations	114
References	115
Arabic Summary	--

List of Abbreviations

ACE	:	Angiotensin converting enzyme
AIP	:	Anaemia in pregnancy
AT	:	Antithrombin
CBC	:	Complete blood count
EPCR	:	Endothelial protein C receptor
HIV	:	Human immunodeficiency virus
HLA	:	Human lymphocyte antigens
IDA	:	Iron deficiency anemia
MCV	:	Mean corpuscular volume
PPI	:	Proton Pump Inhibitors
RDW	:	Red cell distribution width
RES	:	Reticulo-endothelial system
SF	:	Serum ferritin
sTfR	:	Serum transferrin-receptors
TIBC	:	Total iron-binding capacity
TM	:	Thrombomodulin
t-PA	:	Tissue plasminogen activator
TSAT	:	Transferrin saturation
WHO	:	World Health Organization

List of tables

<i>Table</i>	<i>Title</i>	<i>Page</i>
1	Stages of development of iron deficiency anemia	33
2	Risk Factors for Iron Deficiency	36
3	Incidence of Epithelial Lesions in iron deficiency	42
4	Approximate elemental iron content of various oral iron preparations	53
5	Available intravenous iron products	62
6	Shows demographic data of the included women	87
7	Distribution of studied cases as regard gravidity	87
8	Descriptive statistics of initial hemoglobin, blood indices and Serum ferritin levels of all included women	89
9	Difference between both groups concerning demographic data	91
10	Difference between both groups concerning initial hemoglobin, blood indices and serum ferritin	92
11	Difference between both groups concerning hemoglobin & hematocrite after 14 days	93
12	Difference between both groups concerning MCV & MCHC after 14 days	94
13	Difference between both groups concerning serum ferritin after 14 days	95
14	Difference between both groups concerning change in hemoglobin, blood indices and serum ferritin after 14 days	97

List of tables (Cont.)

<i>Table</i>	<i>Title</i>	<i>Page</i>
15	Distribution of studied cases as regard side effects of injected iron	98
16	Difference between both groups concerning side effects	99

List of Figures

<i>Fig.</i>	<i>Title</i>	<i>Page</i>
1	Diagnostic algorithm	51
2	Bar-Chart showing distribution of age among included women	88
3	Pie-Chart showing distribution of parity among included women	88
4	Flow-Chart showing patient's progress through the randomized study	90
5	Box-Plot Chart showing difference between both groups concerning hemoglobin level at day 14 onset of treatment	95
6	Box-Plot Chart showing difference between both groups concerning serum ferritin level at day 14 onset of treatment	96

Introduction

Anemia is the reduction in the normal number of red blood cells and quantity of hemoglobin in the blood. Anemia in pregnancy is defined by the world health organization as a hemoglobin value below 11g/dL (**WHO, 1992**).

Iron deficiency anemia being the most common cause of anemia in pregnancy world wide (**Williams et al., 1992**).

During pregnancy there is an increase in both red cell mass and plasma volume to accommodate the needs of the growing uterus and fetus. The plasma volume increase more than the red cell mass leading to a fall in the concentration of hemoglobin in the blood despite the increase in the total number of red cells. This drop in hemoglobin concentration decrease the blood viscosity and it is thought this enhances the placental perfusion providing a better maternal fetal gas and nutrient exchange (**Mani, 1995**).

Anemia has been associated with general weakness, tiredness and dizziness but the level of hemoglobin associated with these symptoms in pregnancy is un known. Its suggested that the iron stores of the woman's body become reduced during pregnancy (as a result of the increased red cell mass and the demands of fetus exceeding iron intake (**Steer, 1995**).

Knowledge of different hemoglobin cut off levels during pregnancy to differentiate between hydraemia and anemia is important in the first diagnosis. According to the center of disease control data from 1989, lower hemoglobin cut off is 11.0g/dL in the first and last trimester and 10.5g/dL

in the second trimester. Therefore any level below 10.5g/dL should be regarded as anemia and consequently checked (**CDC, 1989**).

Anemia during pregnancy is a well known and considerable risk factor for both mother and fetus. Fetal consequences are an increased risk of growth retardation, prematurity, intrauterine death, amnion rupture and infection. Maternal consequences of anemia are also well known and include cardiovascular symptoms, reduced physical and mental performance, reduced immune function tiredness, reduced peripheral blood reserves and finally increase risk for blood transfusion in the postpartum period (**Breymman, 2002**).

In addition to clinical assessment, laboratory parameters are of major importance for differential diagnosis of anaemia, more than 100 years ago first tests including blood smear, red cell indices and serum iron have been introduced. Later bone marrow stain and most important serum ferritin test have been introduced, ferritin being the actual gold standard for iron status testing. During pregnancy, ferritin shows also weak correlations to other iron parameters and the severity of anaemia, therefore additional tests are helpful (**Broek, et al., 2000**).

The increased iron requirement in pregnancy and the peripartum carry with it an increased susceptibility to iron deficiency and iron deficiency anemia and preoperative blood transfusion (**Breymann, 2002**).

Iron replacement can be given by mouth, intramuscular and intravenous administration. It is also possible to give iron

by giving a blood transfusion and recombinant erythropoietin conjunction with iron is a further possibility (**Mahomed, 2000**).

Oral iron intake is the treatment of choice, and almost all women can be treated effectively with oral preparations. However, parenteral administration of iron is necessary under certain circumstances and may be suitable under following situations: inability to tolerate the effect of orally administered iron, inflammatory bowel disease, peptic ulcer, non compliance with oral regiments (**Singh et al., 1998**).

Parenteral administration of iron provides quick and certain correction of the total iron deficit because it not only corrects the anemia but also builds up iron stores. Parenteral administration of iron can be achieved by either an intramuscular or an intravenous route. Intravenous administered iron can cause anaphylactic shock and all safe guards, such as hospital admission with resuscitation equipment available by the bed side (**Singh, et al., 1998**).

Intramuscular administration of iron is usually achieved by repeated injections of small doses of iron (**Sood et al. 1979**).

Intramuscular administration can be cause discomfort and pain at the injection site and associated with other local complications such as staining of skin, bleeding, formation of sterile abscesses, tissue necrosis or atrophy and sarcoma formation (**Benito et al., 1988**).

Aim of Work

To determine the efficacy of total dose infusion of iron dextran in comparison to intramuscular administration in treatment of iron deficiency anemia during pregnancy.

Hematological Changes with Pregnancy

The major hemodynamic changes induced by pregnancy include an increase in cardiac output, sodium and water retention leading to blood volume expansion, and reduction in systemic vascular resistance and systemic blood pressure. These changes begin early in pregnancy (**Chapman et al., 1998**).

Blood Volume:

The maternal blood volume increases markedly during pregnancy. In studies of normal women, the blood volumes at or very near term are averaged about 40 to 45 percent above their non pregnant levels. The degree of expansion varies considerably. In some women only a modest increase occurs, whereas in others the blood volume nearly doubles. A fetus is not essential for the development of hypervolemia during pregnancy, as increases in blood volume have been demonstrated in some women with hydatidiform mole (**Whittaker et al., 1996**). Pregnancy-induced hypervolemia has several important functions to meet the demands of the enlarged uterus with its greatly hypertrophied vascular system, to protect the mother and in turn the fetus against the deleterious effects of impaired venous return in the supine and

erect positions and to safeguard the mother against the adverse effects of blood loss associated with parturition (**Cunningham et al., 2004**).

Maternal blood volume begins to increase during the first trimester. In fact, by 12 menstrual weeks, the plasma volume expands by approximately 15% as compared with that of prepregnancy. It expands most rapidly during the second trimester, and then rises at a much slower rate during the third trimester to plateau during the last several weeks of pregnancy (**Bernstein et al., 2001**). Blood volume expansion results from an increase in both plasma and erythrocytes. Although more plasma than erythrocytes is usually added to the maternal circulation, the increase in the volume of erythrocytes is considerable, averaging about 450 mL. Moderate erythroid hyperplasia is present in the bone marrow, and the reticulocyte count is elevated slightly during normal pregnancy. This change is almost certainly related to the increase in maternal plasma erythropoietin levels, which peak early during the third trimester and correspond to maximal erythrocyte production (**Clapp et al., 2003**).

Red blood cells mass:

The circulating red cell mass increases by 20-30% during pregnancy, with rises in both cell number and size. It

rises more in women with multiple pregnancies, and substantially more with iron supplementation (29% compared with 17%). In a normal pregnancy the serum iron concentration falls, the absorption of iron from the gut rises and iron-binding capacity rises, since there is increased synthesis of the β 1-globulin transferrin. Plasma folate concentration halves by term, because of greater renal clearance, although red cell folate concentrations fall less. Erythropoietin rises in pregnancy, more if iron supplementation is not taken (55% compared with 25%) but the changes in red cell mass compensate this. Human placental lactogen may be also stimulate haematopoiesis (**Scholl, 2005**).

The Red cell distribution width (RDW) increased significantly between 34 weeks of gestation and labor. No significant changes in RDW occurred between 16 and 34 weeks of gestation, or during the 7 days postpartum (**Shehata, 1998**).

Change in plasma:

The plasma volume increases more than the red cell mass, which leads to a fall in the various concentration measures which include the plasma volume, such as the haematocrit, the haemoglobin concentration and the red cell count. The fall in packed cell volume from 36% in early